Largest psilocybin study continues to grow

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

The world’s largest psilocybin therapy study on depression is approaching completion, and it’s even bigger than expected.

Compass Pathways (CMPS) announced that it’s close to completing its phase 2b trial on treatment-resistant depression, and expects to report the findings by the end of this year. So far, 233 patients have received COMP360 psilocybin therapy, exceeding the target of 216. The company also announced its Q2 financial highlights including $316.3 million in cash and equivalents as of June 30.

PDF of article